Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Ketamine KETTLE trial: a single infusion to ease anorexia distress

NCT ID NCT06736769

Symptom relief Sponsor: Amanda Downey, MD Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only This study
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This Phase 2 trial tests a single intravenous dose of ketamine in 20 hospitalized teens and young adults with anorexia nervosa or atypical anorexia. Researchers want to see if ketamine helps the brain become more flexible, making it easier to learn new, positive associations with food and reducing distress during hospitalization.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
ketamine
What this could lead to
If it works, this could point toward a new way to help hospitalized teens with anorexia feel less distressed and more flexible around food.
What could go wrong
This is a very small, early-phase trial with only 20 people and a single dose. It may not show clear benefits, and ketamine can cause side effects like dizziness or dissociation.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

About 20 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jun 2025

Expected to finish

Jun 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

16 to 26 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Age 16-26 years old 2. Meets diagnosis of anorexia nervosa (AN) or atypical anorexia nervosa (atypical AN) per DSM-5 criteria on admission 3. Admitted to the medical hospital for malnutrition 4. No changes to psychiatric medications for month prior to trial enrollment 5. Agree to use a highly effective form of contraception for at least two weeks following ketamine administration 6. Have an outpatient primary care provider, medical provider, or behavioral health provider or psychiatrist who is actively managing or coordinating care Exclusion Criteria: 1. Lifetime history of any psychotic disorder 2. Moderate or severe substance use disorder 3. Pregnancy as indicated by a positive urine pregnancy test during screening, lactation, or the intention of becoming pregnant within 3 months of entry into this trial 4. Electroconvulsive therapy (ECT) or transcranial magnetic stimulation (TMS) treatment within 30 days prior to enrollment 5. Intellectual or developmental disability 6. High risk for self-harm/suicide 7. Active laxative misuse or abuse 8. Biochemical refeeding syndrome or electrolyte abnormality 9. Cardiac abnormalities identified on admission 10. Taking medications that would be unsafe to administer with ketamine 11. Other medical condition or diagnosis, physical exam finding, laboratory abnormality, or health risk that would increase the risk of adverse events, at the discretion of the investigators

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Anorexia nervosa are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Anorexia anorexia nervosa anxiety disorder Depression Feeding and Eating Disorders

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Anorexia nervosa Atypical anorexia nervosa

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    The full official record for this study. This one lists no contact details, but it is the first place any would appear.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • University of California, San Francisco

    San Francisco, California, 94158, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.